Compare Abeona Therapeutics Inc (ABEO) vs Coursera Inc (COUR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Coursera Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Coursera Inc trades at $5.65 (market cap $1.52B). The key difference: Coursera Inc is far larger — about 3.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | COUR | |
|---|---|---|
Market Cap | $424.33M | $1.52B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $12.20 |
52-Week Low | $4.17 | $5.09 |
Enterprise Value | $279.23M | $778.04M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Coursera (COUR) trades at $5.81, up 4.5% with bullish technical signals and strong analyst support. The company shows improving revenue growth ($757.5M in 2025, projected to $885M in 2026) but remains unprofitable with negative margins. Recent Q2 2026 earnings beat expectations with $0.17 EPS versus $0.10 estimate, while the company made a strategic $100M investment in AI education startup LearnVector.
The stock offers 32% upside to consensus price target of $7.70, supported by 53% buy ratings, but faces execution risks from persistent losses and competitive pressures in online education. Revenue growth trajectory and cost management will be critical for valuation improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
